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NARY RESULTS: Information was retrieved from 6
countries: Belgium, Denmark, Finland, France, Germany,
Italy. Representatives from 5 countries (Austria, Ireland,
Spain, The Netherlands, UK) expressed their will of not
providing data. Information is still expected from 4 coun-
tries (Greece, Luxembourg, Portugal, Sweden). Most of
the respondents deplored the poor quality of HRQL data
provided, leading them to discard HRQL evaluation in
the regulatory process. Nevertheless, 91% expressed
their need for guidance in HRQL issues, and 63% their
need for training. CONCLUSION: HRQL evaluation
currently plays no determining role in the European drug
regulatory process. More efforts should be developed to
improve the quality of HRQL studies, and therefore con-
vince regulators that HRQL is a credible criterion of
evaluation of medicines.
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A number of groups have considered the use of HRQL
assessments for regulatory purposes. The Pharmaceutical
Research and Manufacturers of America (PhRMA) Health
Outcomes Working Group (HOWG), the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR), and the International Society for Quality of Life
Research (ISOQOL) have considered the US regulatory
situation, and the European Regulatory Issues on Quality
of Life Assessment (ERIQA) group has looked at the cur-
rent status in Europe. These groups have each produced
documents intended for the regulatory authorities, sum-
marising the state of the art of HRQL evaluation in clini-
cal trials. A comparison of these documents has been un-
dertaken, with the aim of highlighting areas of agreement
and dissent and identifying those issues in need of further
consideration. Seven topics have been considered when
reviewing the documents: concepts (definitions and ter-
minology), rationale for HRQL evaluation, instruments,
study design, data analysis, interpretation and conditions
for HRQL claims. Within each topic, issues addressed by
all or only some of the initiatives have been identified,
and recommendations made (if any) have been com-
pared. For a number of issues, recommendations are con-
sistent between the various initiatives. For example, all
recommend that it should be a requirement to justify the
choice of an HRQL questionnaire, and to provide details
of the psychometric properties of instruments used. By
contrast, there is a lack of consensus concerning the num-
ber of trials required to support an HRQL promotional
claim. This work indicates that collaboration between
the various groups is essential to reach an optimal degree
of agreement. It is proposed that a conference be organ-
ised in the final quarter of the year 2000 involving dele-
gates from each initiative with the objective of achieving
harmonisation of recommendations to be made to regu-
latory authorities.
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Studies have individually examined the impact of copay-
ment level changes and prescription expenditure caps on
total health care service utilization and costs in managed
care plans. OBJECTIVE: We examined the impact of a
change in prescription benefit that included both changes
in copayment levels as well as prescription reimburse-
ment limits on health care service utilization and charges.
The change in prescription benefit included a change
from $200 quarterly reimbursement cap to unlimited ge-
neric coverage and $25 monthly cap in brand-name drug
reimbursements with a decrease in copayment for generic
drugs from $7 to $5 per prescription. METHODS: A co-
hort of 3116 older adults continuously enrolled in a
Medicare managed care plan from January 1998 were
followed up for health care service utilization and charges
before and after introduction of the change effective Jan-
uary 1999. Multiple regression analyses were conducted
to examine the impact of the prescription coverage
change, after adjusting for demographic, clinical, and
medication-related variables. RESULTS: Analysis of pa-
tient data in the first six months of the two years showed
that the prescription benefit change was associated with a
33% decrease in prescription charges, and a 9% decrease
in health care service charges. There was an increase of
5% in the health care service utilization and 9% increase
in the number of prescriptions filled, but the 10% in-
crease in the generic prescriptions, and small reduction in
length of hospital stay accounted for the overall reduc-
tion in total health care charges. CONCLUSION: The
change in prescription benefit with a lower brand-name
cap and lower generic copayment increased the generic
drug utilization and decreased total health care charges.
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OBJECTIVE: The National Cooperative Growth Study
(NCGS) is an observational registry that monitors out-
comes in children treated with growth hormone (GH).
METHODS: As of June 30, 1999, data had been col-
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lected on more than 33,000 GH treated children and ap-
proximately 17,000 untreated children. Since 1996, chil-
dren referred for evaluation of short stature have also
been followed. RESULTS: Both groups had severe short
stature, but children who received GH were significantly
shorter (HtSDS  2.6  1.1) than those who did not
(HtSDS  2.2  0.9, P  0.0001). GH deficiency was
the most common indication for GH treatment (64%);
other diagnoses in the GH treated group included Turner
syndrome (11%), renal insufficiency (3%) and idiopathic
short stature (ISS) (18%). The patients with ISS were
shorter (HtSDS  2.8  0.9) than those with GHD
(HtSDS  2.5  1.2, P  0.0001). CONCLUSIONS:
Children treated with GH have severe short stature.
